$18.7B Gene Editing Market by 2030 CASGEVY First CRISPR therapy approved (Dec 2023) 47.6% CAGR Gene therapy market growth FDA 3.0 Accelerating genetic medicine approvals Prime Editing Search-and-replace DNA technology Vertex + CRISPR $11.1B partnership value $18.7B Gene Editing Market by 2030 CASGEVY First CRISPR therapy approved (Dec 2023) 47.6% CAGR Gene therapy market growth FDA 3.0 Accelerating genetic medicine approvals Prime Editing Search-and-replace DNA technology Vertex + CRISPR $11.1B partnership value
Precision Genome Engineering

The Future of Gene Editing Is Here

From CRISPR-Cas9 to prime editing, gene modification technologies are revolutionizing medicine. Correct genetic mutations, cure inherited diseases, and engineer next-generation cell therapies.

Acquire Domain Explore Technology
A T C G
$18.7B
Gene Editing Market 2030
47.6%
CAGR 2024-2030
90%+
On-Target Editing Efficiency
4
FDA-Approved Gene Therapies (2024)

Precision Editing Technologies

From cutting to writing - the evolution of genome engineering

✂

CRISPR-Cas9

The revolutionary molecular scissors that enabled precise DNA cutting. Nobel Prize-winning technology (2020) now powering approved therapies for sickle cell disease and beta thalassemia.

✎

Base Editing

Single-nucleotide precision without double-strand breaks. Directly converts one base pair to another. Beam Therapeutics advancing multiple clinical programs for genetic blood disorders.

🔎

Prime Editing

Search-and-replace DNA editing. Can make all 12 types of point mutations plus small insertions and deletions. Prime Medicine leading clinical development for this next-gen platform.

🔬

In Vivo Delivery

Lipid nanoparticles and AAV vectors delivering editors directly to tissues. Intellia's NTLA-2001 showed 87% transthyretin reduction with single IV dose in human trials.

🧬

Ex Vivo Cell Engineering

Edit cells outside the body, then return them to patients. Powers CAR-T therapies and CASGEVY for sickle cell. Enables quality control before administration.

🚀

Epigenome Editing

Regulate gene expression without changing DNA sequence. Reversible modifications using CRISPR-based activators and repressors. Chroma Medicine pioneering epigenetic therapies.

Gene Editing Leaders

Companies advancing the precision medicine revolution

Company Technology Lead Programs Status
CRISPR Therapeutics CRISPR-Cas9 CASGEVY (sickle cell, beta-thal) FDA Approved
Intellia Therapeutics In Vivo CRISPR NTLA-2001 (ATTR amyloidosis) Phase III
Beam Therapeutics Base Editing BEAM-101 (sickle cell) Phase I/II
Prime Medicine Prime Editing PM359 (chronic granulomatous) Phase I
Editas Medicine CRISPR-Cas12a EDIT-301 (sickle cell) Phase I/II
Verve Therapeutics Base Editing VERVE-101 (hypercholesterolemia) Phase I
Chroma Medicine Epigenome Editing Gene silencing platform Preclinical
Vertex Pharmaceuticals CRISPR Partner CASGEVY commercialization Commercial

Own the Gene Editing Brand

GeneEditing.app - Premium domain for the precision medicine era. Perfect for platforms, education, or therapeutic development.

Contact for Pricing
Redirecting to PatientAnalog.com in 20s